OmniAb
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 106
- Market Cap
- $509.2M
- Introduction
OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
FDA Clears Expedited Pathway for Tharimmune's TH104 Opioid Defense Drug Without Additional Clinical Trials
Tharimmune received positive FDA feedback allowing a 505(b)(2) NDA submission for TH104 as prophylaxis against ultrapotent opioid exposure, with no additional clinical trials required.
© Copyright 2025. All Rights Reserved by MedPath